JP6134331B2 - アミロイドベータペプチド関連の疾患または症状の予防または治療のための医薬組成物 - Google Patents
アミロイドベータペプチド関連の疾患または症状の予防または治療のための医薬組成物 Download PDFInfo
- Publication number
- JP6134331B2 JP6134331B2 JP2014546303A JP2014546303A JP6134331B2 JP 6134331 B2 JP6134331 B2 JP 6134331B2 JP 2014546303 A JP2014546303 A JP 2014546303A JP 2014546303 A JP2014546303 A JP 2014546303A JP 6134331 B2 JP6134331 B2 JP 6134331B2
- Authority
- JP
- Japan
- Prior art keywords
- polar solvent
- pharmaceutical composition
- isoacteoside
- water
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 42
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title claims description 32
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title claims description 32
- 201000010099 disease Diseases 0.000 title claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 25
- 208000024891 symptom Diseases 0.000 title claims description 13
- 230000002265 prevention Effects 0.000 title claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 86
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims description 72
- 239000002798 polar solvent Substances 0.000 claims description 52
- FNMHEHXNBNCPCI-QEOJJFGVSA-N Isoacteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](COC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H]1O FNMHEHXNBNCPCI-QEOJJFGVSA-N 0.000 claims description 38
- FNMHEHXNBNCPCI-RYEKTNFUSA-N isoacteoside Natural products C[C@@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](COC(=O)C=Cc3ccc(O)c(O)c3)O[C@@H](OCCc4ccc(O)c(O)c4)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O FNMHEHXNBNCPCI-RYEKTNFUSA-N 0.000 claims description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 229930185474 acteoside Natural products 0.000 claims description 34
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 claims description 34
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 229930182470 glycoside Natural products 0.000 claims description 32
- 150000002338 glycosides Chemical class 0.000 claims description 32
- 238000009825 accumulation Methods 0.000 claims description 15
- 239000012046 mixed solvent Substances 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 239000011324 bead Substances 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 201000000166 CST3-related cerebral amyloid angiopathy Diseases 0.000 claims description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims description 3
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 208000028389 Nerve injury Diseases 0.000 claims description 3
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 3
- 206010034010 Parkinsonism Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 201000008319 inclusion body myositis Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 230000007087 memory ability Effects 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- 230000008764 nerve damage Effects 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 19
- 239000003814 drug Substances 0.000 description 13
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 12
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 206010029260 Neuroblastoma Diseases 0.000 description 5
- 238000006384 oligomerization reaction Methods 0.000 description 5
- 241000336316 Cistanche tubulosa Species 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 description 3
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/10—Chewing gum characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576367P | 2011-12-16 | 2011-12-16 | |
| US61/576,367 | 2011-12-16 | ||
| PCT/CN2012/086796 WO2013087042A1 (zh) | 2011-12-16 | 2012-12-17 | 预防或治疗淀粉样β肽相关疾病或状况的医药组合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500300A JP2015500300A (ja) | 2015-01-05 |
| JP2015500300A5 JP2015500300A5 (https=) | 2016-02-12 |
| JP6134331B2 true JP6134331B2 (ja) | 2017-05-24 |
Family
ID=48580733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546303A Active JP6134331B2 (ja) | 2011-12-16 | 2012-12-17 | アミロイドベータペプチド関連の疾患または症状の予防または治療のための医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150087606A1 (https=) |
| EP (1) | EP2792361B1 (https=) |
| JP (1) | JP6134331B2 (https=) |
| KR (1) | KR102048289B1 (https=) |
| CN (1) | CN103156867B (https=) |
| AU (1) | AU2012350437B2 (https=) |
| CA (1) | CA2859227C (https=) |
| MY (1) | MY171048A (https=) |
| SG (1) | SG11201403265VA (https=) |
| TW (1) | TWI488630B (https=) |
| WO (1) | WO2013087042A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015154721A1 (zh) * | 2014-04-10 | 2015-10-15 | 杏辉天力（杭州）药业有限公司 | 异类叶升麻苷衍生物及其制造方法与用途 |
| TWI650131B (zh) | 2014-07-03 | 2019-02-11 | 杏輝藥品工業股份有限公司 | 管花肉蓯蓉萃取物之用於製備保護眼部細胞之藥品或食品用途 |
| CN104922137B (zh) * | 2015-06-04 | 2018-07-31 | 苏州大学 | 苯乙醇苷类化合物Torenoside B的新用途 |
| KR102018085B1 (ko) * | 2017-12-06 | 2019-09-04 | 김좌진 | 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물 |
| KR102135148B1 (ko) * | 2019-08-28 | 2020-07-20 | 김좌진 | 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물 |
| CN110812375A (zh) * | 2019-12-12 | 2020-02-21 | 中国海洋大学 | 一种老鼠簕中苯乙醇苷类提取物及其制备方法与作为抗肝损伤药物的应用 |
| CN111632058A (zh) * | 2020-06-24 | 2020-09-08 | 新疆医科大学 | 毛蕊花糖苷在制备预防和治疗神经退行性疾病药物中的应用 |
| CN112225766A (zh) * | 2020-10-27 | 2021-01-15 | 杏辉天力（杭州）药业有限公司 | 一种由肉苁蓉萃取物中富集及分离苯乙醇苷类化合物的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100500584B1 (ko) * | 2002-08-12 | 2005-07-12 | 경희대학교 산학협력단 | 신경성장인자와 유사 작용을 갖는 육종용 추출물 및 이를함유하는 조성물 |
| KR100514076B1 (ko) * | 2003-01-10 | 2005-09-13 | 주식회사 엘컴사이언스 | 페닐에타노이드 유도체를 포함하는 퇴행성 뇌신경계질환의 예방 및 치료용 조성물 |
| TW200416036A (en) * | 2003-02-18 | 2004-09-01 | Sinphar Pharmaceutical Co Ltd | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same |
| CN1268341C (zh) * | 2003-03-04 | 2006-08-09 | 杏辉天力（杭州）药业有限公司 | 来源于管花肉苁蓉的含有苯乙醇苷的制剂及其制备方法和用途 |
| CN100345857C (zh) * | 2004-07-16 | 2007-10-31 | 北京华医神农医药科技有限公司 | 一种从肉苁蓉药材中提取、分离松果菊苷的方法 |
| EP1736167B1 (en) * | 2005-06-20 | 2018-03-21 | I.R.B. Istituto Di Ricerche Biotecnologiche S.r.l. | Extracts obtained from cell line cultures from Syringa vulgaris IRB-SV25/B (DMS:16857), their preparation and use |
| JP5410683B2 (ja) | 2008-02-19 | 2014-02-05 | 学校法人近畿大学 | カンカニクジュヨウから得られる肝保護剤及び抗ＴＮＦ−α作用剤 |
| CN101411753B (zh) * | 2008-12-04 | 2012-02-29 | 闫明 | 列当总苷在制备抗老年痴呆的药物中的应用 |
| CN101797307B (zh) * | 2010-04-09 | 2011-08-10 | 广州中医药大学 | 一种含苯乙醇苷的枇杷叶紫珠提取物及其制备方法 |
| TWI486162B (zh) * | 2010-06-16 | 2015-06-01 | Sinphar Pharmaceutical Co Ltd | 異類葉升麻苷或其醫藥學上可接受之鹽於抑制澱粉樣β肽生成、累積或聚集、以及製備預防或治療澱粉樣β肽相關疾病或狀況的藥物之用途 |
| CN102670631B (zh) * | 2011-12-01 | 2013-07-31 | 河南科技大学 | 一种四楞麻总苯乙醇苷组合物、制备方法及应用 |
-
2012
- 2012-12-17 CA CA2859227A patent/CA2859227C/en active Active
- 2012-12-17 US US14/365,404 patent/US20150087606A1/en not_active Abandoned
- 2012-12-17 MY MYPI2014001777A patent/MY171048A/en unknown
- 2012-12-17 CN CN201210548516.0A patent/CN103156867B/zh active Active
- 2012-12-17 TW TW101147781A patent/TWI488630B/zh active
- 2012-12-17 JP JP2014546303A patent/JP6134331B2/ja active Active
- 2012-12-17 SG SG11201403265VA patent/SG11201403265VA/en unknown
- 2012-12-17 EP EP12856624.7A patent/EP2792361B1/en active Active
- 2012-12-17 KR KR1020147018051A patent/KR102048289B1/ko active Active
- 2012-12-17 WO PCT/CN2012/086796 patent/WO2013087042A1/zh not_active Ceased
- 2012-12-17 AU AU2012350437A patent/AU2012350437B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2859227C (en) | 2019-01-22 |
| EP2792361A4 (en) | 2015-05-13 |
| EP2792361B1 (en) | 2019-03-27 |
| AU2012350437B2 (en) | 2017-06-29 |
| KR20150002576A (ko) | 2015-01-07 |
| CA2859227A1 (en) | 2013-06-20 |
| MY171048A (en) | 2019-09-23 |
| TWI488630B (zh) | 2015-06-21 |
| JP2015500300A (ja) | 2015-01-05 |
| CN103156867B (zh) | 2019-04-30 |
| EP2792361A1 (en) | 2014-10-22 |
| CN103156867A (zh) | 2013-06-19 |
| SG11201403265VA (en) | 2014-09-26 |
| TW201325597A (zh) | 2013-07-01 |
| AU2012350437A1 (en) | 2014-07-31 |
| KR102048289B1 (ko) | 2020-01-08 |
| US20150087606A1 (en) | 2015-03-26 |
| WO2013087042A1 (zh) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6134331B2 (ja) | アミロイドベータペプチド関連の疾患または症状の予防または治療のための医薬組成物 | |
| Berking | Bud formation in hydra: Inhibition by an endogenous morphogen | |
| JP2013526487A (ja) | リンゴの皮由来のフェノール組成物およびその使用 | |
| JP7577351B2 (ja) | 新規エラジタンニンおよび口腔用剤 | |
| KR101845862B1 (ko) | 특발성 폐섬유증의 치료 또는 예방을 위한 약학적 조성물 | |
| CN110974906A (zh) | 促进神经元新生的医药组合物以及利用天麻萃取物或腺苷类似物促进神经元新生的方法 | |
| JP2015500300A5 (https=) | ||
| Koppula et al. | Anti-fibrotic effects of Orostachys japonicus A. Berger (Crassulaceae) on hepatic stellate cells and thioacetamide-induced fibrosis in rats | |
| JP5968878B2 (ja) | イソアクテオシドまたはその製薬上許容される塩の使用 | |
| CN105440103B (zh) | 从皱纹盘鲍鲍鱼内脏中分离的抗炎肽及其用途 | |
| EP3558334B1 (en) | Compositions | |
| JP4994222B2 (ja) | 血小板凝集抑制剤 | |
| US10576108B2 (en) | Tau protein production accelerator, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by tau protein deficiency | |
| JP2013035795A (ja) | 新規フェニルエタノイド配糖体及び皮膚化粧料 | |
| JP6293402B2 (ja) | Ｔｉｅ２活性化剤、血管新生抑制剤、血管の成熟化剤、及び血管の正常化剤、並びに飲食品 | |
| JP6543536B2 (ja) | 神経細胞死抑制剤 | |
| JP6436475B2 (ja) | 血管攣縮抑制剤 | |
| JP5723010B2 (ja) | 認知症の予防または治療用組成物 | |
| KR102429147B1 (ko) | 콜라비론의 제조방법 | |
| JP6969041B2 (ja) | 血管内皮型一酸化窒素合成酵素産生促進剤及び経口用組成物 | |
| CN102949469B (zh) | 唐松草提取物制备治疗老年痴呆症药物的用途 | |
| JPH0418100A (ja) | 神経栄養活性抑性物質 | |
| JP2011068594A (ja) | セリンパルミトイルトランスフェラーゼｍＲＮＡ発現促進剤 | |
| WO2014139227A1 (zh) | 一种块糖、生产方法及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160920 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160916 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170220 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170404 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170421 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6134331 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |